An MoU was signed between Jamnagar based Institute of Teaching and Research in Ayurveda (ITRA) under the Ministry of Ayush and the Government of Gujarat in the presence of the Deputy Chief Minister of Gujarat Shri Nitinbhai Patel and Secretary, Ministry of AyushVaidya Rajesh Kotecha on 15th July 2021.
Through this MoU, all the institutions functioning in the Ayurveda campus in Jamnagar have been brought under the umbrella of ITRA, the only institution under the Ministry of Ayush that has been accorded the status of Institute of National Importance (INI). Underlining the importance of the MoU, shriNitinbhai said that this will pave the way of the strengthening of the education system in all branches of Ayurveda.
The MoU was exchanged between the Director, ITRA, Prof. Dr. Anup Thakar and Shri H.P. Jhala, I/C Registrar, Gujarat Ayurveda University.
“This arrangement will result, in due course, in the opening of new doors in the fields of education, research and medicine,” said the Deputy CM on the occasion of the signing ceremony. It is hoped that in the field of Ayurveda, it will be easier to prepare new teaching, medical and research methods and the study-research process will be intensified, expanding the overall scope of Ayurveda education and research.
Addressing the gathering, Vaidya Rajesh Kotecha said that in the field of Ayurveda, it will be easier to prepare new teaching, medical and research methods. He said that the study and research process can be made more in-depth and ITRA will be an exemplary institution for Ayurveda education and reshaping research institutes across the country.
Read in Hindi► इंस्टीट्यूट ऑफ टीचिंग एंड रिसर्च इन आयुर्वेद (आईटीआरए) और गुजरात सरकार के बीच समझौते पर हस्ताक्षर
Tokyo - Researchers have found that a fermented soybean dish often served for breakfast in Japan, can prove to be effective against SARS-CoV-2, the virus that causes Covid-19.
Natto is made by fermenting soybeans with Bacillus subtilis, a bacteria found in plants and in soil.
Researchers from the Tokyo University of Agriculture and Technology (TUAT) found that the extract made from the sticky, strong smelling natto may inhibit the ability of the SARS-CoV-2 virus to infect cells.
"Traditionally, Japanese people have assumed that natto is beneficial for their health," said Tetsuya Mizutani, director of the Center for Infectious Disease Epidemiology and Prevention Research at the TUAT.
"In recent years, research studies have revealed scientific evidence for this belief. In this study, we investigated natto's antiviral effects on SARS-CoV-2, the virus that causes Covid-19, and bovine herpesvirus 1 (BHV-1), which causes respiratory disease in cattle," Mizutani added.
The findings were published in the journal Biochemical and Biophysical Research Communications.
The team prepared two natto extracts from the food, one with heat and one without. They applied the extracts to sets of lab-cultured cells from cattle and from humans. One set was infected with SARS-CoV-2, while the other set was infected with BHV-1.
When treated with the natto extract made without heat, both SARS-CoV-2 and BHV-1 lost the ability to infect cells. However, neither virus appeared to be affected by the heat-treated natto extract.
"We found what appears to be a protease or proteases -- proteins that metabolise other proteins -- in the natto extract directly digests the receptor binding domain on the spike protein in SARS-CoV-2," Mizutani said, noting that the protease appears to break down in heat, losing the ability to digest proteins and letting the virus remain infectious.
The spike protein sits on the virus's surface and binds to a receptor on host cells. With an inactive spike protein, SARS-CoV-2 cannot infect healthy cells. The researchers found a similar effect on BHV-1 as well as the Alpha Covid variant.
While the results are promising, Mizutani also cautioned that further studies are needed to identify the exact molecular mechanisms at work. He also stressed that the research does not provide any evidence of reduced viral infection simply by eating natto. Once the components are identified and their functions verified, the researchers plan to advance their work to clinical studies in animal models. (IANS)
Kolkata, July 14 (IANS) Keeping in mind the imminent threat of the third wave, the West Bengal government has decided not to take any risk and continue on with the Covid-induced restrictions till July 30, with some relaxations.Though the state has not allowed trains to operate, it has opened up some more areas, allowing relaxations to people and providing more business opportunities.In an order, the state government said: "All shops & markets (essential and non-essential commodities) may remain open as per usual operational hours. Retail shops in shopping malls and market complexes may remain open as per usual operational hours with 50 per cent workforce and restricted entry of people/customers up to 50 per cent at a time." It, however, said that the night curfew time - from 9 p.m. to 5 p.m. - will remain, thus making it clear that that all business establishments will have close by 9 p.m.Banks, which were, so far, allowed to function till 2 p.m., have been allowed one more hour. Banks and financial institutions shall remain open for restricted hours between 10 a.m. to 3 p.m. and for operations of ATMS, the order said.The state also said that parks may remain open for morning walks, physical exercise etc during 6 a.m. to 9 p.m. but only vaccinated people shall be allowed. Gyms shall be allowed to remain open during 6 a.m. to 10 a.m. and 4 p.m. to 8 p.m. with 50 per cent capacity in each session, provided the employees/staff and customers have been vaccinated, and subject to regular sanitisation.Salons and beauty parlours may remain open as per usual operational hours with 50 per cent of seating capacity at a time, provided the employees/staff and customers have been vaccinated, and subject to regular sanitisation.The state ordered that all cinema halls, spas, and swimming pools shall continue to remain closed but the last may be opened exclusively for routine practice of state, national and international level swimmers from 6 a.m. to 10 a.m.Metro railway service shall operate 5 days a week with 50 per cent seating capacity and shall remain suspended on Saturdays and Sundays. Regular sanitisation of the metro, wearing of masks and appropriate Covid compliant discipline by passengers shall be ensured by the metro authorities and the local administration.However, there has not been any major changes in the transport system. Though there was a huge demand for the opening up of local trains, the state government decided to keep them suspended for another 15 days. "Intra-state local train movement shall remain closed except for staff special trains for movement of emergency and essential services personnel," the order said.Movement of public transport including intra-state (inter-district) government and private buses, inland waterways transport, trams, local taxis, cabs and auto-rickshaws will be allowed with passengers not more than 50 per cent of seating capacity at a time, subject to vaccination of drivers and other staff, regular sanitisation of vehicle, and mandatory wearing of masks by all users.All schools, colleges, universities, polytechnics and Anganwadi centres and other educational and academic institutions shall continue to remain closed, the order said. In addition, all political, social, cultural, academic and entertainment related gatherings, groupings and congregations shall continue to be prohibited. Not more than 50 persons shall be allowed at a time in marriage ceremonies and related gatherings, and 20 at funeral rituals, the order stated.--IANSsaibal/vd
New Delhi, July 4 (IANS) Two more Central Drug Laboratories have been readied at Pune and Hyderabad for Covid vaccine testing, in the wake of the Covid-19 pandemic, and considering the enhanced production of Covid vaccines, the government said on Sunday.According to a Science & Technology Ministry statement, the facility at the National Centre for Cell Science, Pune, has now been notified as a Central Drugs Laboratory for testing and lot release of Covid-19 vaccines, through a gazette notification issued by the Health & Family Welfare Ministry on June 28.The facility at the National Institute of Animal Biotechnology, Hyderabad is likely to receive necessary notification shortly, it said."With generous support from PM CARES Fund trust in a very short span of time, both the institutions, through relentless efforts, have set up the state-of-the-art modern facilities for this purpose."The facilities are expected to test approx 60 batches of vaccines per month. The facilities are geared up to test existing Covid-19 vaccines and other newer Covid-19 vaccines as per demand of the nation. This will not only expedite the vaccine manufacture and supply but also be logistically convenient considering that both Pune and Hyderabad are the two vaccine manufacturing hubs," the statement said.Currently, India has a Central Drugs Laboratory (CDL) at Kasauli, which is the National Control Laboratory for testing and pre-release certification of immunobiologicals (vaccines and antisera) meant for human use in India.The Department of Biotechnology, under the Science & Technology Ministry, now has set up facilities in its autonomous research institutes, the NCCS, and the NIAB, for batch testing and quality control of vaccines.--IANSmiz/vd
Tokyo, July 2 (IANS) A team of scientists has identified an anti-malarial drug, mefloquine, that is effective against SARS-CoV-2, the virus causing Covid-19.The team from Tokyo University of Science and others mathematically modelled the effectiveness of mefloquine to predict its potential real-world impact, if applied to treat Covid-19.They found that mefloquine could reduce the overall viral load in affected patients to under 7 per cent and shorten the "time-till-virus-elimination" by 6.1 days. Their findings are published in Frontiers in Microbiology.To identify drugs with higher antiviral potency than existing antivirals, the team first screened approved anti-parasitic/anti-protozoal drugs.They found that mefloquine had the highest anti-SARS-CoV-2 activity among the tested compounds. Upon testing it against other quinoline derivatives, such as hydrochloroquine, in a cell line mimicking the cell-based environments of human lung cells, they found it to be better."In our cell assays, mefloquine readily reduced the viral RNA levels when applied at the viral entry phase but showed no activity during virus-cell attachment. This shows that mefloquine is effective on SARS-COV-2 entry into cells after attachment on cell surface," said lead scientist Koichi Watashi, from the varsity.To bolster mefloquine's antiviral activity, the scientists looked into the possibility of combining it with a drug that inhibits the replication step of SARS-CoV-2: Nelfinavir.Interestingly, they observed that the two drugs acted in "synergy" and the drug combination showed greater antiviral activity than either showed alone, without being toxic to the cells in the cell lines themselves.While the study must be succeeded by clinical trials, "the world can hope that mefloquine becomes a drug used to effectively treat patients with Covid-19," the researchers noted.--IANSrvt/vd
Tokyo, June 27 (IANS) A novel vaccine to protect against deadly cholera which can be simply mixed with liquid and drunk is safe, results of the first human trial has shown.The vaccine, named MucoRice-CTB, made by grinding up genetically modified grains of rice has shown no obvious side effects and a good immune response, said researchers from the University of Tokyo and Chiba University in Japan. They have published the peer-reviewed results of the Phase 1 clinical trial of the vaccine in The Lancet Microbe.The MucoRice-CTB vaccine is grown in rice plants and stimulates immunity through the mucosal membranes of the intestines. It remains stable at room temperature, can be stored and transported without refrigeration and does not need needles. It can be taken by simply mixing with liquid."I'm very optimistic for the future of our MucoRice-CTB vaccine, especially because of the dose escalation results. Participants responded to the vaccine at the low, medium and high doses, with the largest immune response at the highest dose," said Professor Hiroshi Kiyono, from the Institute of Medical Science at the Tokyo University.For the study, 30 volunteers received a placebo and groups of 10 volunteers received a total of four doses spaced every two weeks of either 3 milligrams (mg), 6 mg or 18 mg each of the vaccine. Tests two and four months after receiving the last dose revealed that volunteers who responded to the vaccine had IgA and IgG antibodies -- two types of proteins the immune system produces to fight infections -- specific to cholera toxin B (CTB). Participants who received a higher dose of vaccine were more likely to have CTB-specific antibodies.The new cholera vaccine grows in genetically modified Japanese short-grain rice plants in a purpose-built, indoor hydroponic farm. When the plants are mature, the rice is harvested and ground into a fine powder, then sealed in aluminum packets for storage. When people are ready to be vaccinated, the powder is mixed with about 90 milliliters (1/3 US cup) of liquid and then drunk.Researchers have only tested the vaccine using saline (a salt solution equivalent to body fluids), but they expect it would work equally well with plain water.--IANSrvt/sdr/